Prevention of breast cancer using selective oestrogen receptor modulators (SERMs)
Placebo controlled trials in over 25,000 women showed that tamoxifen reduced breast cancer risk by about 40% and osteoporotic fracture risk by about 32%. Similarly placebo controlled trials in nearly 18,000 women showed that raloxifene reduced breast cancer risk by 44–72% and osteoporotic fractures...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2006
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779496/ |